Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
NCT05868733Phase 2Recruiting
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Mar 2024
- Primary completion
- Jun 2027
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of rVSV∆G-LASV-GPC in Lassa fever (9 cohorts), sponsored by International AIDS Vaccine Initiative. Primary endpoint: Safety and Tolerability of rVSV∆G-LASV-GPC Vaccine at 7 months. Started Mar 2024; status: recruiting.
02
Drugs
rVSV∆G-LASV-GPC
03
Conditions
Lassa fever
Beyond the preview
Go deeper on NCT05868733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868733.